Ingrid Hopper Mbbs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6609156/publications.pdf

Version: 2024-02-01

84 papers

3,879 citations

201674 27 h-index 60 g-index

85 all docs 85 docs citations

85 times ranked 4691 citing authors

#	Article	IF	CITATIONS
1	Comparison of cutaneous facial temperature using infrared thermography to standard temperature measurement in the critical care setting. Journal of Clinical Monitoring and Computing, 2022, 36, 1029-1036.	1.6	6
2	Patient Reported Outcome Measures After Breast Augmentation $\hat{a} \in \text{``Using the BREAST-Q IS. Patient}$ Related Outcome Measures, 2022, Volume 13, 1-8.	1.2	6
3	Management of heart failure in older people. Journal of Pharmacy Practice and Research, 2022, 52, 72-79.	0.8	2
4	Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. Atherosclerosis, 2022, 346, 68-74.	0.8	7
5	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL) Tj ETQq $1\ 1$	0.784314 13.7	rgBT /Over
6	Cognitive Decline and Risk of Dementia in Individuals With Heart Failure: A Systematic Review and Meta-analysis. Journal of Cardiac Failure, 2022, 28, 1337-1348.	1.7	18
7	Impact of a model of care for heart failure inâ€patients to reduce variation in care: a quality improvement project. Internal Medicine Journal, 2021, 51, 557-564.	0.8	3
8	Sub-Clinical Effects of Outdoor Smoke in Affected Communities. International Journal of Environmental Research and Public Health, 2021, 18, 1131.	2.6	1
9	Breast Device Surgery in Australia: Early Results from the Australian Breast Device Registry. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2021, 74, 2719-2730.	1.0	3
10	Identification of Factors Predictive for Patient Reported Outcomes in the Prospective Australian Breast Device Registry. Aesthetic Surgery Journal, 2021, , .	1.6	1
11	Infrared thermography as a modality for tracking cutaneous temperature change and post-mortem interval in the critical care setting. Forensic Science International, 2021, 327, 110960.	2.2	2
12	Final opinion on the safety of breast implants in relation to anaplastic large cell lymphoma: Report of the scientific committee on health, emerging and environmental risks (SCHEER). Regulatory Toxicology and Pharmacology, 2021, 125, 104982.	2.7	38
13	Test-Retest Reliability of the BREAST-Q IS in the Australian Breast Device Registry. Aesthetic Surgery Journal, 2021, 41, NP177-NP184.	1.6	2
14	Complementary medicine use by communityâ€dwelling older Australians. Medical Journal of Australia, 2021, 214, 140-141.	1.7	3
15	Nutraceuticals in Patients With Heart Failure: A Systematic Review. Journal of Cardiac Failure, 2020, 26, 166-179.	1.7	14
16	Estimation of respiratory rate using infrared video in an inpatient population: an observational study. Journal of Clinical Monitoring and Computing, 2020, 34, 1275-1284.	1.6	15
17	Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension, 2020, 75, 23-32.	2.7	61
18	Effectiveness of <i>Curcuma longa</i> Extract for the Treatment of Symptoms and Effusion–Synovitis of Knee Osteoarthritis. Annals of Internal Medicine, 2020, 173, 861-869.	3.9	68

#	Article	IF	CITATIONS
19	Toward International Harmonization of Breast Implant Registries: International Collaboration of Breast Registry Activities Global Common Data Set. Plastic and Reconstructive Surgery, 2020, 146, 255-267.	1.4	24
20	The National Dutch Breast Implant Registry: user-reported experiences and importance. European Journal of Plastic Surgery, 2020, 43, 751-766.	0.6	2
21	Novel wearable and contactless monitoring devices to identify deteriorating patients in the clinical setting: a systematic review protocol. Systematic Reviews, 2020, 9, 104.	5. 3	7
22	Withdrawal of antihypertensive drugs in older people. The Cochrane Library, 2020, 2020, CD012572.	2.8	31
23	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Tj ETQq1 1 1444-1451.	l 0.784314 13.7	4 rgBT /Overlo 351
24	Lessons Learned in Implementing Patient-Reported Outcome Measures (PROMs) in the Australian Breast Device Registry (ABDR). Aesthetic Surgery Journal, 2020, , .	1.6	3
25	The Utility of Predicting Hospitalizations Among Patients With Heart Failure Using mHealth: Observational Study. JMIR MHealth and UHealth, 2020, 8, e18496.	3.7	5
26	Towards a strategy for clinical quality registries in Australia. Australian Health Review, 2019, 43, 284.	1.1	9
27	Temporal Changes in Characteristics, Treatment and Outcomes of Heart Failure Patients Undergoing Percutaneous Coronary Intervention Findings From Melbourne Interventional Group Registry. Heart Lung and Circulation, 2019, 28, 1018-1026.	0.4	0
28	Qualified privilege legislation to support clinician quality assurance: balancing professional and public interests. Medical Journal of Australia, 2019, 210, 343.	1.7	5
29	Response to "Comments on â€~Patient-Reported Outcome Measures for Breast Implant Surgery: A Pilot Study'― Aesthetic Surgery Journal, 2019, 39, NP404-NP405.	1.6	0
30	Establishing patientâ€reported outcome measures for the Breast Device Registry. ANZ Journal of Surgery, 2019, 89, 266-267.	0.7	3
31	Evaluating recruitment strategies for <scp>AUSPICE</scp> , a large Australian communityâ€based randomised controlled trial. Medical Journal of Australia, 2019, 210, 409-415.	1.7	12
32	Physicians' guideline adherence is associated with longâ€term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. European Journal of Heart Failure, 2019, 21, 921-929.	7.1	86
33	Patient-Reported Outcome Measures for Breast Implant Surgery: A Pilot Study. Aesthetic Surgery Journal, 2019, 39, 314-321.	1.6	28
34	All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. American Journal of Therapeutics, 2019, 26, e671-e678.	0.9	6
35	Defining Quality Indicators for Breast Device Surgery. Plastic and Reconstructive Surgery - Global Open, 2019, 7, e2348.	0.6	8
36	Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. Cardiovascular Research, 2019, 115, 266-276.	3.8	38

#	Article	IF	CITATIONS
37	Impact of socioeconomic status on incident heart failure and left ventricular dysfunction: systematic review and meta-analysis. European Heart Journal Quality of Care & Elinical Outcomes, 2019, 5, 169-179.	4.0	42
38	Establishing the acceptability of a brief patient reported outcome measure and feasibility of implementing it in a breast device registry – a qualitative study. Journal of Patient-Reported Outcomes, 2019, 3, 63.	1.9	10
39	United we stand, divided we conquer: pilot study of multidisciplinary General Medicine Heart Failure Care Program. Internal Medicine Journal, 2018, 48, 178-183.	0.8	3
40	Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry. Cardiovascular Drugs and Therapy, 2018, 32, 57-64.	2.6	4
41	Mind the Gap: Mismatches Between Clinicians and Patients in Heart Failure Medication Management. Cardiovascular Drugs and Therapy, 2018, 32, 37-46.	2.6	4
42	Cosmetic tourism for breast augmentation: a systematic review. ANZ Journal of Surgery, 2018, 88, 842-847.	0.7	19
43	Retention of medical records of patients with highâ€risk medical devices. Medical Journal of Australia, 2018, 209, 461.	1.7	0
44	Systematic review with metaâ€analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Alimentary Pharmacology and Therapeutics, 2018, 48, 780-796.	3.7	48
45	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet, The, 2018, 391, 2346-2355.	13.7	597
46	High risk device registries: Global value, costs, and sustainable funding. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2018, 71, 1362-1380.	1.0	10
47	Clinical quality registries for clinicianâ€level reporting: strengths and limitations. Medical Journal of Australia, 2018, 208, 323-323.	1.7	4
48	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018. Medical Journal of Australia, 2018, 209, 363-369.	1.7	31
49	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart Lung and Circulation, 2018, 27, 1123-1208.	0.4	262
50	Breast Implant Registries: A Call to Action. Aesthetic Surgery Journal, 2018, 38, 807-810.	1.6	13
51	Observational studies and their utility for practice. Australian Prescriber, 2018, 41, 82-85.	1.0	30
52	Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1426-1435.	2.8	46
53	Australian Breast Device Registry: breast device safety transformed. ANZ Journal of Surgery, 2017, 87, 9-10.	0.7	20
54	Breast Implant–Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk. Plastic and Reconstructive Surgery, 2017, 140, 645-654.	1.4	295

#	Article	IF	CITATIONS
55	Sympathetic Response and Outcomes Following Renal Denervation in Patients With Chronic Heart Failure: 12-Month Outcomes From the Symplicity HF Feasibility Study. Journal of Cardiac Failure, 2017, 23, 702-707.	1.7	44
56	Pilot for the Australian Breast Device Registry (ABDR): a national opt-out clinical quality registry for breast device surgery. BMJ Open, 2017, 7, e017778.	1.9	10
57	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet, The, 2017, 390, 2160-2170.	13.7	597
58	Improving the safety of breast implants: implantâ€associated lymphoma. Medical Journal of Australia, 2017, 207, 185-186.	1.7	7
59	Clinical quality registries for clinicianâ€level reporting: strengths and limitations. Medical Journal of Australia, 2017, 206, 427-429.	1.7	18
60	Chronic heart failure. Australian Prescriber, 2017, 40, 128-136.	1.0	17
61	Neurohormonal Blockade in Heart Failure. Cardiac Failure Review, 2017, 03, 19.	3.0	53
62	Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). American Heart Journal, 2016, 177, 58-65.	2.7	33
63	Attitudes of Patients and Prescribing Clinicians to Polypharmacy and Medication Withdrawal in Heart Failure. Journal of Cardiac Failure, 2016, 22, 743-744.	1.7	7
64	The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice. Heart Failure Reviews, 2016, 21, 675-697.	3.9	39
65	Comorbidities in Heart Failure: Are There Gender Differences?. Current Heart Failure Reports, 2016, 13, 1-12.	3.3	37
66	Polypharmacy in heart failure $\hat{a} \in \text{``}$ Is reducing medication safe?. International Journal of Cardiology, 2016, 214, 529-530.	1.7	4
67	Probable fenofibrate-induced acute generalized exanthematous pustulosis. American Journal of Health-System Pharmacy, 2015, 72, 2061-2063.	1.0	6
68	Digoxin Withdrawal Worsens Clinical Status in Stable Patients With Heart Failure Receiving Optimal Contemporaneous Therapyâ€"A Randomized Controlled Trial. Journal of Cardiac Failure, 2015, 21, 779-781.	1.7	7
69	The Ongoing Evolution of Optimal ClinicalÂEndpoints for Heart Failure Trials â^—. JACC: Heart Failure, 2015, 3, 615-617.	4.1	2
70	Neprilysin inhibitors preserve renal function in heart failure. International Journal of Cardiology, 2015, 179, 329-330.	1.7	27
71	Warfarin brands. Australian Prescriber, 2015, 38, 150-151.	1.0	0
72	Celiac Disease and Drug Absorption: Implications for Cardiovascular Therapeutics. Cardiovascular Therapeutics, 2014, 32, 253-256.	2.5	7

#	Article	IF	CITATIONS
73	Heart failure and dipeptidyl peptidaseâ€4 inhibitors. European Journal of Heart Failure, 2014, 16, 603-607.	7.1	23
74	Worsening renal function during renin–angiotensin–aldosterone system inhibitor initiation and longâ€ŧerm outcomes inÂpatients with left ventricular systolic dysfunction. European Journal of Heart Failure, 2014, 16, 41-48.	7.1	104
75	Can Medications be Safely Withdrawn in Patients With Stable Chronic Heart Failure? Systematic Review and Meta-analysis. Journal of Cardiac Failure, 2014, 20, 522-532.	1.7	36
76	Dipeptidyl Peptidaseâ€4 Inhibitors and Cardiovascular Outcomes: Metaâ€Analysis of Randomized Clinical Trials with 55,141 Participants. Cardiovascular Therapeutics, 2014, 32, 147-158.	2.5	111
77	Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: A meta-analysis of >35,000 patients. International Journal of Cardiology, 2014, 173, 197-203.	1.7	26
78	Statins in CHF. Heart Lung and Circulation, 2014, 23, 988.	0.4	O
79	Updated metaâ€analysis on antithrombotic therapy in patients with heart failure and sinus rhythm. European Journal of Heart Failure, 2013, 15, 69-78.	7.1	41
80	Impact of heart failure and changes to volume status on liver stiffness: nonâ€invasive assessment using transient elastography. European Journal of Heart Failure, 2012, 14, 621-627.	7.1	69
81	Adverse Drug Reactions during Hospital Stay: Evaluation of a Model for Informing Patients. Journal of Pharmacy Practice and Research, 2012, 42, 95-99.	0.8	5
82	Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 813-823.	2.8	122
83	Cardiac effects of non-cardiac drugs. Australian Prescriber, 2011, 34, 52-54.	1.0	4
84	Withdrawal of antihypertensive drugs in older people. The Cochrane Library, 0, , .	2.8	3